A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Nura A., Ahmetaj-Shala, Blerina, Duluc, Lucie, Mackenzie, Louise S., Kirkby, Nicholas S., Reed, Daniel M., Lickiss, Paul D., Davies, Robert P., Freeman, Gemma R., Wojciak-Stothard, Beata, Chester, Adrian H., El-Sherbiny, Ibrahim M., Mitchell, Jane A., Yacoub, Magdi H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830862/
https://www.ncbi.nlm.nih.gov/pubmed/26960567
http://dx.doi.org/10.1007/s12265-016-9684-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830862/
https://www.ncbi.nlm.nih.gov/pubmed/26960567
http://dx.doi.org/10.1007/s12265-016-9684-2

Ejemplares similares